What does it do?
Kamada is a growth-stage biopharmaceutical company that earns money by manufacturing and selling protein-based medicines extracted from human plasma. The process begins with the collection of human plasma, from which Kamada extracts specific proteins to treat rare and serious conditions like Alpha-1 Antitrypsin deficiency and rabies. It sells these proprietary products globally through partnerships and its own sales force, while also operating a distribution arm that brings third-party medicines to the Israeli and Middle Eastern markets.
Where does revenue come from?
Proprietary products account for 86% of total revenue, with the remainder coming from the distribution of third-party medicines. The proprietary segment includes six FDA-approved therapies, with flagship products like Glassia for lung disease and KEDRAB for rabies being the primary drivers. Most of these sales are concentrated in the United States and international markets, while the distribution segment focuses on the Israeli healthcare system.
Revenue by Geography
Who are its customers?
Kamada serves a global network of hospitals, specialty pharmacies, and large biopharmaceutical partners who rely on its plasma extraction expertise. While it does not disclose a total user count like a consumer app, its impact is measured by the sale of its six core FDA-approved therapies to specialized medical providers. In 2025, the company reported total revenues of $180.5 million, a 12% increase from the prior year, supported by its growing distribution business which launched additional biosimilar products in Israel. It also recently signed a $50 million three-year agreement to supply plasma to a leading global biopharma firm, adding a massive corporate client to its base.
What gives it staying power?
Kamada relies on a regulatory moat because its plasma-derived products require highly specialized FDA-approved manufacturing facilities that are difficult for rivals to replicate. Biologic drugs have higher switching costs than standard pills because doctors are often reluctant to change a stable patient's specialized treatment.
Where is it headed?
The company is making a major strategic bet on vertical integration by opening its own plasma collection centers in the United States. Management aims to secure its own supply of specialty plasma to lower costs and capture more profit from every unit sold. If this works, Kamada will move from being a simple manufacturer to a fully independent biotech powerhouse with a secured supply chain.
The business is in a clear acceleration phase, with 2025 revenue reaching a record $180.5 million and net income jumping 40% year-over-year. This growth is more than just a one-year spike; it reflects the successful integration of its acquired product portfolio and higher utilization of its manufacturing plant.
Cash generation is high-quality, with 2025 free cash flow of $20 million tracking closely with net income. This indicates that reported profits are turning into actual bankable cash, which the company used to pay its first cash dividend of $0.25 per share in early 2026.
Kamada maintains a very conservative balance sheet with a total debt-to-equity ratio of just 0.04x. Sitting on $73 million in cash as of March 2026, the company is financially positioned to fund its new Texas plasma centers or pursue further acquisitions without needing to borrow heavily.
Kamada is a financially strong business entering its most profitable chapter as it pivots toward vertical integration.
Management successfully delivered record 2025 results with an adjusted EBITDA of $42 million, a 23% increase over 2024. This was achieved by shifting the mix toward its own high-margin proprietary products and ending expensive research projects that were not yielding results.
Gross margins dipped to 42% in the latest quarter from 47% a year ago, primarily due to a shift in the mix of products sold. Investors should watch if the new U.S. plasma collection centers can push margins back toward the high 40s by lowering the cost of raw materials.
The specialty generics and plasma-derived therapy market is roughly $107 billion today and is projected to reach $122 billion by 2027. This is a high-barrier industry where pricing power is structural because the manufacturing process for biologics is regulated, complex, and capital-intensive. Kamada occupies a valuable niche as a specialist player in rare conditions like rabies and lung disease. While it is much smaller than the industry giants, its focus on specific "orphan" treatments gives it a clear runway for growth as it expands distribution.
The plasma industry is a rational market dominated by a few massive players who prioritize margin over aggressive price wars. Entry barriers are exceptionally high because building an FDA-approved plasma plant takes years and hundreds of millions of dollars. Competition is based on manufacturing reliability and securing a stable supply of human plasma.
Giant competitors like Takeda and CSL threaten Kamada through their massive R&D budgets and global sales reach. Takeda’s scale allows it to bundle products, while CSL owns hundreds of collection centers that give it a lower cost per liter of plasma. The most dangerous threat is a larger rival launching a more convenient synthetic or recombinant version of Kamada's plasma-derived proteins.
Kamada is currently holding its ground by aggressively expanding its own distribution into new regions like the Middle East and North Africa. Its recent $50 million supply agreement proves it can compete for major biopharma contracts.
Kamada's primary protection is its intangible assets, specifically its proprietary manufacturing processes and FDA-approved product licenses. Producing these proteins from plasma is a "black box" process that is difficult for generic competitors to copy without years of clinical trials. Its six FDA-approved products serve as a high wall that keeps simple generic rivals out.
The numbers tell a story of a business that is finally beginning to harvest its investments. A net margin of 11% and record profits in 2025 demonstrate that Kamada's niche focus is consistently profitable. The 23% growth in EBITDA last year proves that its advantage is translating into higher returns for shareholders.
The rating is capped at Narrow because Kamada lacks the massive, global collection network that would give it a Wide cost advantage. While it is building its own centers, it still depends on external partners for a portion of its raw plasma supply. Its relatively small size means it cannot yet dictate market pricing against the global giants.
The moat is strengthening as the company moves toward full vertical integration. Every new plasma center it opens in Texas makes its business more durable and less dependent on the global market price of plasma.
Delivered record 2025 results and met revenue guidance for three consecutive years.
Initiated first cash dividend of $14.4 million while maintaining $73 million in net cash.
FIMI Opportunity Funds owns 38% of the company, ensuring a deep shareholder-first orientation.
Capital Allocation Track Record
Amir London has proven to be a highly effective operator who successfully transitioned Kamada from a research-heavy biotech into a profitable, commercial-stage enterprise. His decision to cut ties with underperforming clinical trials in favor of buying profitable, already-approved products was a masterclass in pragmatic leadership. The management team has earned high credibility by hitting their 2025 financial targets in the middle of a significant regional conflict in Israel, showing remarkable resilience and operational focus.
The most significant governance risk is the concentration of ownership under FIMI Opportunity Funds, which holds 38% of the company. While this ensures strong alignment between the board and large shareholders, it could potentially limit the influence of smaller investors. However, the presence of a professional private equity firm as a controlling owner generally provides a credible bench and disciplined oversight that mitigates key-person risk surrounding any single executive.
We expect revenue to grow from $0.2B in FY2026 to $0.3B in FY2031 (~11% CAGR), with EPS growing from $0.43 to $1.02 (~19% CAGR). Growth is driven by the continued market penetration of the acquired plasma-derived protein portfolio and the expansion of the international distribution business. Profitability improves as specialized manufacturing facilities reach higher utilization levels, spreading fixed production costs over a larger volume of units. EPS grows faster Operating margin expected to reach ~24% by FY2031.
Vertical integration expands gross margins toward 50% threshold. Owning the plasma collection process in Texas allows Kamada to capture the full profit margin that was previously lost to third-party suppliers.
Global distribution expansion into MENA and Latin America. Leveraging its existing FDA-approved portfolio to enter new geographic markets provides a low-cost path to double-digit revenue growth.
New M&A to acquire complementary plasma-derived therapies. With $73 million in cash and no debt, Kamada is positioned to buy more products that it can plug into its existing sales infrastructure.
Escalation of regional conflict disrupts Israeli manufacturing base. Since the primary plant is located in Israel, a significant expansion of conflict could lead to supply chain shutdowns or export delays.
Regulatory setbacks or manufacturing audits at new plasma centers. Any FDA citation at the new Texas facilities could delay the company's timeline for reaching plasma self-sufficiency and hurt margins.
Synthetic alternatives displace traditional plasma-derived therapies. Long-term development of recombinant proteins by larger rivals could eventually commoditize Kamada's traditional blood-derived product line.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Normalized P/E approach — calculating the company's average earning power over its current growth cycle. This framework fits Kamada because the company has recently pivoted from high research spending to consistent GAAP profitability (standard accounting profits), making current earnings a cleaner signal than revenue. By averaging earnings over a three-year window, we avoid over-valuing the stock based on a single high-growth year or a temporary spike in demand.
We multiply our average earnings estimate of $0.46 by a 24x P/E multiple to reach our $11 fair value. Our 24x multiple sits above mature specialty generic peers like Hikma (12x) or Viatris (8x) but remains in line with high-growth specialty biotechs like Emergent BioSolutions (18x), reflecting Kamada’s superior organic growth and new $50 million contract visibility. Our $0.46 earnings base is the average of the 2025 actual results ($0.35), the 2026 forecast ($0.43), and the 2027 projection ($0.61) from the report's data engine, which "smooths" the transition into this higher-profitability phase.
A Forward P/E cross-check produces a fair value of $10.98 — almost identical to our $11 result, which strongly confirms the answer. For this check, we applied a more conservative 18x peer-average multiple to the 2027 earnings projection of $0.61 per share. The close alignment between the two methods suggests that even if we use a lower multiple on a future-year profit target, the company's rapid growth trajectory supports a double-digit share price. We trust the Normalized P/E slightly more because it accounts for the potential volatility in biopharma earnings during a manufacturing ramp-up.
We're assuming Kamada's operating profit margins sustain at 15% through 2028. This is reasonable because the company is now vertically integrated (meaning it owns more of its supply chain) after getting FDA approval for its own plasma collection center in San Antonio, which lowers the cost of raw materials.
We're assuming the $50 million plasma supply agreement signed in July 2026 is fully realized over three years. This contract provides high revenue visibility and is supported by Kamada's expanded manufacturing capacity, making it a reliable driver of the 13% revenue growth forecast for the coming year.
We're assuming a 24x P/E multiple — the price investors pay for every $1 of yearly profit. This is justified because Kamada is shifting from a small-scale manufacturer to a profitable biopharma owner with high-growth specialty products, which typically commands a premium over traditional generic drug makers.
The biggest risk is a disruption in the specialty plasma supply chain that could significantly spike manufacturing costs. This would likely compress the price-to-earnings multiple (what investors pay for each dollar of profit) from 24x to 15x, knocking approximately $4 off the per-share fair value. Watch the "Cost of Goods Sold" as a percentage of revenue for any move above 62% as an early warning signal.
Bear case ($7): Profit margins drop by more than 3 percentage points if the San Antonio plasma center fails to scale quickly; or Annual revenue growth in the Proprietary Products segment falls below 8% due to new competition in the U.S. market.
Bull case ($15): The company secures a second $50 million-plus plasma supply agreement within the next 18 months; or New biosimilar (lower-cost versions of biologic drugs) launches in Israel exceed $10 million in annual sales by 2027.
Clearthesis wrote this report from 38 sources, including SEC filings, analyst estimates, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on August 7, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.